Imexpharm Corp 2025 AR2
The report highlights Imexpharm's performance in 2025, during which the company achieved a gross revenue of VND 2,914 billion, representing a 16% year-on-year growth, and a profit before tax of VND 446 billion. Key achievements included the launch of IMECEF, Vietnam's first EU-GMP first generic antibiotic, and maintaining its leading position in the domestic antibiotic market for the third consecutive year. The company also obtained the Investment Registration Certificate for the Cat Khanh Pharmaceutical Factory Complex Project and accelerated its digital transformation by upgrading to SAP S/4HANA.
Company: Imexpharm Corp
Sector: Health Care
Country: Vietnam
Year: 2025
Type: AR2
Pages: 144
Imexpharm Corp
Annual Report
The report highlights Imexpharm's performance in 2025, during which the company achieved a gross revenue of VND 2,914 billion, representing a 16% year-on-year growth, and a profit before tax of VND 446 billion. Key achievements included the launch of IMECEF, Vietnam's first EU-GMP first generic antibiotic, and maintaining its leading position in the domestic antibiotic market for the third consecutive year. The company also obtained the Investment Registration Certificate for the Cat Khanh Pharmaceutical Factory Complex Project and accelerated its digital transformation by upgrading to SAP S/4HANA.
Sign in for free to access detailed sustainability data, reporting standards, and ESG metrics.
Document Details
Report Year
2025
Reporting Period
Jan 1, 2025 - Dec 31, 2025
Fiscal Year
2025
Type
Annual Report with Sustainability Disclosures
Language
English
Pages
File Size
Standards & Assurance
Reporting Standards
Materiality Assessment
ESG Data?Experimental — AI-extracted data, may contain inaccuracies
Emissions
Scope 1:
Scope 2:
Water Consumption
Women on Board
Employees